Cases & Investigations

In re Niaspan Antitrust Litigation

CASE NUMBER: 2:13-md-02460
PRACTICE AREAS: Antitrust
PRODUCT: Niaspan (extended release niacin)
CASE STATUS: Pending
COURT: United States District Court for the Eastern District of Pennsylvania

On December 23, 2013, Berger Montague was appointed co-lead counsel in this class action challenging a pay for delay deal concerning the brand name drug Niaspan (extended release niacin). On September 8, 2014, the Honorable Jan E. DuBois denied defendants’ motion to dismiss. Discovery has closed and class certification briefing has completed.

Lead Attorneys: David F. Sorensen, Andrew Curley, Nick Urban

Lead Attorneys

David Sorensen Headshot

David F. Sorensen

Managing Shareholder
Andrew Curley Headshot

Andrew C. Curley

Shareholder

Associates

Request A Free Consultation